Myocardial Fibrosis - Pipeline Review, H1 2017

  • ID: 4311839
  • Report
  • 68 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Evotec AG
  • Galectin Therapeutics Inc
  • GTx Inc
  • Invivosciences Inc
  • MandalMed Inc
  • Merck & Co Inc
  • MORE
Myocardial Fibrosis - Pipeline Review, H1 2017

Summary:

The latest Pharmaceutical and Healthcare disease pipeline guide Myocardial Fibrosis - Pipeline Review, H1 2017, provides an overview of the Myocardial Fibrosis (Cardiovascular) pipeline landscape.

Myocardial fibrosis is an abnormal thickening of the heart valves due to inappropriate proliferation of cardiac fibroblasts. Symptoms include chest pain, some abdominal swelling, nausea and fatigue.

Report Highlights:

The latest Pharmaceutical and Healthcare latest pipeline guide Myocardial Fibrosis - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Myocardial Fibrosis (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Myocardial Fibrosis (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Myocardial Fibrosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase I, Preclinical and Discovery stages are 1, 9 and 4 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Myocardial Fibrosis (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Myocardial Fibrosis (Cardiovascular).
  • The pipeline guide reviews pipeline therapeutics for Myocardial Fibrosis (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Myocardial Fibrosis (Cardiovascular) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Myocardial Fibrosis (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Myocardial Fibrosis (Cardiovascular)
Reasons to Buy:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Myocardial Fibrosis (Cardiovascular).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Myocardial Fibrosis (Cardiovascular) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Evotec AG
  • Galectin Therapeutics Inc
  • GTx Inc
  • Invivosciences Inc
  • MandalMed Inc
  • Merck & Co Inc
  • MORE
  1. Introduction
  2. Myocardial Fibrosis - Overview
  3. Myocardial Fibrosis - Therapeutics Development
  4. Pipeline Overview
  5. Pipeline by Companies
  6. Pipeline by Universities/Institutes
  7. Products under Development by Companies
  8. Products under Development by Universities/Institutes
  9. Myocardial Fibrosis - Therapeutics Assessment
  10. Assessment by Target
  11. Assessment by Mechanism of Action
  12. Assessment by Route of Administration
  13. Assessment by Molecule Type
  14. Myocardial Fibrosis - Companies Involved in Therapeutics Development
  15. Daewoong Pharmaceutical Co Ltd
  16. Evotec AG
  17. Galectin Therapeutics Inc
  18. GTx Inc
  19. Invivosciences Inc
  20. Lead Discovery Center GmbH
  21. MandalMed Inc
  22. Merck & Co Inc
  23. miRagen Therapeutics Inc
  24. TRACON Pharmaceuticals Inc
  25. Myocardial Fibrosis - Drug Profiles
  26. carotuximab - Drug Profile
  27. Product Description
  28. Mechanism Of Action
  29. R&D Progress
  30. Drugs for Tissue Fibrosis - Drug Profile
  31. Product Description
  32. Mechanism Of Action
  33. R&D Progress
  34. DWN-10290 - Drug Profile
  35. Product Description
  36. Mechanism Of Action
  37. R&D Progress
  38. GMCT-01 - Drug Profile
  39. Product Description
  40. Mechanism Of Action
  41. R&D Progress
  42. GRMD-02 - Drug Profile
  43. Product Description
  44. Mechanism Of Action
  45. R&D Progress
  46. GTx-878 - Drug Profile
  47. Product Description
  48. Mechanism Of Action
  49. R&D Progress
  50. Monoclonal Antibodies to Inhibit Marinobufagenin for Cardiovascular Diseases - Drug Profile
  51. Product Description
  52. Mechanism Of Action
  53. R&D Progress
  54. MRG-201 - Drug Profile
  55. Product Description
  56. Mechanism Of Action
  57. R&D Progress
  58. NM-922 - Drug Profile
  59. Product Description
  60. Mechanism Of Action
  61. R&D Progress
  62. Recombinant Protein to Inhibit Galectin-3 for Myocardial Fibrosis and Oncology - Drug Profile
  63. Product Description
  64. Mechanism Of Action
  65. R&D Progress
  66. Small molecules to Inhibit CYP11B2 for Cardiovascular Diseases - Drug Profile
  67. Product Description
  68. Mechanism Of Action
  69. R&D Progress
  70. Small Molecules to Inhibit RhoGEF12 for Cardiovascular Diseases - Drug Profile
  71. Product Description
  72. Mechanism Of Action
  73. R&D Progress
  74. SP-20102 - Drug Profile
  75. Product Description
  76. Mechanism Of Action
  77. R&D Progress
  78. TPI-2049 - Drug Profile
  79. Product Description
  80. Mechanism Of Action
  81. R&D Progress
  82. TRC-205 - Drug Profile
  83. Product Description
  84. Mechanism Of Action
  85. R&D Progress
  86. Myocardial Fibrosis - Dormant Projects
  87. Myocardial Fibrosis - Product Development Milestones
  88. Featured News & Press Releases
  89. Aug 05, 2014: Galectin Therapeutics Receives U.S. Patent for GR-MD-02 Composition of Matter
  90. Appendix
  91. Methodology
  92. Coverage
  93. Secondary Research
  94. Primary Research
  95. Expert Panel Validation
  96. Contact Us
  97. Disclaimer
List of Tables:
  1. Number of Products under Development for Myocardial Fibrosis, H1
  2. Number of Products under Development by Companies, H1
  3. Number of Products under Development by Universities/Institutes, H1
  4. Products under Development by Companies, H1
  5. Products under Development by Universities/Institutes, H1
  6. Number of Products by Stage and Target, H1
  7. Number of Products by Stage and Mechanism of Action, H1
  8. Number of Products by Stage and Route of Administration, H1
  9. Number of Products by Stage and Molecule Type, H1
  10. Myocardial Fibrosis - Pipeline by Daewoong Pharmaceutical Co Ltd, H1
  11. Myocardial Fibrosis - Pipeline by Evotec AG, H1
  12. Myocardial Fibrosis - Pipeline by Galectin Therapeutics Inc, H1
  13. Myocardial Fibrosis - Pipeline by GTx Inc, H1
  14. Myocardial Fibrosis - Pipeline by Invivosciences Inc, H1
  15. Myocardial Fibrosis - Pipeline by Lead Discovery Center GmbH, H1
  16. Myocardial Fibrosis - Pipeline by MandalMed Inc, H1
  17. Myocardial Fibrosis - Pipeline by Merck & Co Inc, H1
  18. Myocardial Fibrosis - Pipeline by miRagen Therapeutics Inc, H1
  19. Myocardial Fibrosis - Pipeline by TRACON Pharmaceuticals Inc, H1
  20. Myocardial Fibrosis - Dormant Projects, H1
List of Figures:
  1. Number of Products under Development for Myocardial Fibrosis, H1
  2. Number of Products under Development by Companies, H1
  3. Number of Products by Targets, H1
  4. Number of Products by Stage and Targets, H1
  5. Number of Products by Mechanism of Actions, H1
  6. Number of Products by Stage and Top 10 Mechanism of Actions, H1
  7. Number of Products by Routes of Administration, H1
  8. Number of Products by Stage and Routes of Administration, H1
  9. Number of Products by Molecule Types, H1
  10. Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Daewoong Pharmaceutical Co Ltd
  • Evotec AG
  • Galectin Therapeutics Inc
  • GTx Inc
  • Invivosciences Inc
  • Lead Discovery Center GmbH
  • MandalMed Inc
  • Merck & Co Inc
  • miRagen Therapeutics Inc
  • TRACON Pharmaceuticals Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll